Oruka Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2015
Net Income	-83.72	-5.34	-9.93	-19.32	-9.74	Upgrade
Depreciation & Amortization	0.15	0.11	0.11	0.09	0.09	Upgrade
Share-Based Compensation	14.92	0.69	0.56	0.5	0.04	Upgrade
Other Operating Activities	10.81	-0.47	-1.66	-0.03	1.88	Upgrade
Operating Cash Flow	-57.84	-5.01	-10.91	-18.76	-7.73	Upgrade
Capital Expenditures	-0.19	0	-0	-0.04	-0.02	Upgrade
Change in Investments	-329.94	0	0	0	0	Upgrade
Investing Cash Flow	-330.13	0	-0	-0.04	-0.02	Upgrade
Share Issuance / Repurchase	416.69	0	0	24.07	50.89	Upgrade
Debt Issued / Paid	0	0	0	0	-0.41	Upgrade
Other Financing Activities	32.85	-	-	-0.98	-2.03	Upgrade
Financing Cash Flow	449.54	0	0	23.09	48.45	Upgrade
Net Cash Flow	61.58	-5.01	-10.91	4.29	40.71	Upgrade
Free Cash Flow	-58.03	-5.01	-10.91	-18.81	-7.74	Upgrade
Free Cash Flow Per Share	-3.46	-4.17	-9.09	-16.23	-19.73	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).